Enhanced parmacokinetic profile of hydrophobic dopamine agonists administered to the dermis
OwnerThomas C. Pinkertoninventor
Life of this patent
Estimating the term…
Abstract
A method for systemic administration of a hydrophobic dopamine agonist to a mammal is disclosed. The method involves delivering the hydrophobic dopamine agonist to the dermis of the mammal whereby improved systemic absorption is obtained compared to absorption produced upon delivering the substance subcutaneously by bolus administration.
Claims102
A method for systemic administration of a hydrophobic dopamine agonist having a logP of about 1.5 or greater to a mammal, the method comprising delivering the dopamine agonist by bolus injection to the dermis of the mammal, wherein increased systemic absorption is produced as compared to absorption produced upon delivering the dopamine agonist subcutaneously by bolus injection.
A method for administration of a hydrophobic dopamine agonist having a logP of about 1.5 or greater to a mammal, the method comprising selectively delivering the dopamine agonist by bolus injection to the dermis of the mammal to obtain systemic absorption of the dopamine agonist from the dermis.
A method for administration of a hydrophobic dopamine agonist have a logP of about 1.5 or greater to a mammal, the method comprising selectively delivering the dopamine agonist by bolus injection to the dermis of the mammal wherein systemic absorption of the dopamine agonist from the dermis is obtained.
A method for administration of a hydrophobic dopamine agonist having a logP of about 1.5 or greater to a mammal, the method comprising selectively delivering the dopamine agonist by bolus injection to the dermis of the mammal to achieve a substantially higher bioavailability and/or a substantially higher Cmax and/or a substantially shorter Tmax and/or a substantially shorter Tlag, and/or a substantially greater Ka as compared to that produced upon bolus subcutaneous administration of the dopamine agonist at an identical dose.
A method for administration of a hydrophobic dopamine agonist having a logP of about 1.5 or greater to a mammal, the method comprising selectively delivering the dopamine agonist by bolus injection to the dermis of the mammal wherein a substantially higher bioavailability and/or a substantially higher Cmax and/or a substantially shorter Tmax and/or a substantially shorter Tlag, and/or a substantially greater Ka is produced as compared to that produced upon bolus subcutaneous administration of the dopamine agonist at an identical dose.
Dependencies are inferred from the claim text.